BioGenomics
BioGenomics Limited is an India-based biopharmaceutical company developing and manufacturing biosimilar drugs for diabetes (insulin analogs, GLP-1 agonists) and cancer (anti-PD-1 mAbs, Filgrastim), alongside AOF recombinant enzymes and ELISA kits for biopharmaceutical manufacturers, backed by Oman Investment Authority.
- Company typePrivate
- Founded2002
- HeadquartersThane, India
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioGenomics does
BioGenomics Limited is an India-based biopharmaceutical company founded in 2002 and headquartered in Thane (near Mumbai), focused on developing and manufacturing biosimilar drugs for diabetes and cancer, alongside animal-origin-free (AOF) recombinant enzymes and ELISA detection kits for biopharmaceutical manufacturing. The company has a portfolio spanning insulin analogs (Insulin Aspart, Glargine, Lispro, Degludec and combinations), GLP-1 receptor agonists (Liraglutide, Tirzepatide, Exenatide), and oncology biosimilars (Pembrolizumab, Nivolumab, Filgrastim), plus a diabetic foot ulcer candidate (BGN-25). Its enzyme product line includes GMP-grade Recombinant Trypsin (TrypPRO, TrypCELL, TrypSOL), Carboxypeptidase B (CarboxyB), Enterokinase (EKDK), and ELISA kits (Residual Trypsin, Residual CPB, Host Cell Protein detection).
The company's core technology is an indigenous biopharmaceutical platform covering cell lines, proprietary super vectors for mammalian and microbial expressions, codon-optimized gene sequences, protein folding technologies, and novel purification/isolation technologies — protected by over 127 patents across co-founder Dr. Sanjay Sonar (100+) and Whole-Time Director Dr. Archana Krishnan (27+). Manufacturing runs on bacterial expression systems under strict animal-origin-free conditions to minimize pathogen contamination risk. BioGenomics is privately held, backed by Oman Investment Authority, and operates a WHO GMP, EU-GMP, and PIC/s compliant facility in Pondicherry, with new manufacturing capacity under construction in Sanand (450 KG drug substance, 20M cartridges/6M vials drug product per annum, designed for US FDA/EMA) and a fill+finish plant in Oman (20M cartridges for MENA).
BioGenomics operates a B2B business model with partnership-based go-to-market. For biosimilars, the company develops and manufactures while partnering with country-specific pharmaceutical segment leaders for commercialization — exemplified by its 2023 partnership with USV to launch INSUQUICK, the first biosimilar Insulin Aspart in India. For recombinant enzymes and ELISA kits, the company sells directly to global biopharmaceutical manufacturers under quote-based pricing. Revenue is generated through one-time license/product sales across the biopharmaceutical and enzyme product lines. The 200+ headcount includes 70+ scientists, and the company holds ISO 9001:2015, ISO 14001, ISO 18001, DSIR approval, and GLP, EMA, GCP compliance certifications.
BioGenomics firmographics
Firmographics- Name
- BioGenomics
- Legal name
- BioGenomics Limited
- Website
- https://biogenomics.co.in
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- BioGenomics Limited is an India-based biopharmaceutical company developing and manufacturing biosimilar drugs for diabetes (insulin analogs, GLP-1 agonists) and cancer (anti-PD-1 mAbs, Filgrastim), alongside AOF recombinant enzymes and ELISA kits for biopharmaceutical manufacturers, backed by Oman Investment Authority.
- Ownership category
- akta.pro rank
BioGenomics industry classification
Industry- Product category
- Biosimilar Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Insulin & Analog Biosimilars (HLAIAFAB)
- akta.pro secondary industries
- Recombinant Protein Biosimilars (hormones, enzymes, cytokines) (HLAAAHAB), Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)
Keywords
Where BioGenomics is headquartered
LocationHeadquarters
- HQ city
- Thane
- HQ country
- India
- HQ region
- Asia
Offices4 records
Markets served
BioGenomics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Infrastructure, Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Revenue model
- Biopharmaceutical Products: Sale of biosimilar drugs including insulin analogs (Insulin Aspart, Insulin Glargine, Insulin Lispro, Insulin Degludec), GLP-1 inhibitors (Liraglutide, Tirzepatide, Exenatide), and anti-cancer products (Pembrolizumab biosimilar, Nivelumab biosimilar, Filgrastim).
- Recombinant Proteins and Enzymes: Sale of GMP-grade recombinant enzymes including Trypsin (TrypPRO, TrypCELL, TrypSOL), Carboxypeptidase B (CarboxyB), Enterokinase (EKDK), and ELISA kits for biopharmaceutical manufacturing.
- ELISA Detection Kits: Sale of Residual Trypsin Detection Kit, Residual CPB Detection Kit, and Host Cell Protein Detection Kit for quality control in biopharmaceutical manufacturing.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
BioGenomics product offering
Product offeringCore offering
BioGenomics develops and manufactures biosimilar biopharmaceuticals focused on anti-diabetes (insulin analogs and GLP-1 receptor agonists) and anti-cancer (monoclonal antibody biosimilars, Filgrastim) therapeutics using an indigenous recombinant protein platform. The company also produces Animal Origin Free (AOF) GMP-grade recombinant enzymes (Trypsin, Carboxypeptidase B, Enterokinase) and ELISA detection kits (residual Trypsin, residual CPB, Host Cell Protein) used by other biopharmaceutical manufacturers.
Product overview
BioGenomics is an Indian biopharmaceutical company developing a comprehensive portfolio of biosimilar drugs focused on anti-diabetes and anti-cancer therapeutics. The product portfolio consists of multiple insulin analog biosimilars (rapid-acting, long-acting, and ultra-long-acting formulations including Insulin Aspart, Glargine, Lispro, Degludec, and combinations), GLP-1 receptor agonists (Liraglutide, Exenatide, Tirzepatide), oncology biologics (Pembrolizumab and Nivolumab biosimilars, Filgrastim), and a diabetic foot ulcer ointment (BGN-25). The company also manufactures Animal Origin Free (AOF) recombinant enzymes including Trypsin (TrypPRO, TrypCELL, TrypSOL formats), Carboxypeptidase B, and Enterokinase for biopharmaceutical manufacturing. Supporting diagnostic products include ELISA kits for residual enzyme detection (Trypsin, CPB) and Host Cell Protein detection. BioGenomics operates GMP manufacturing facilities in Puducherry (fill-finish) and is constructing facilities in Sanand, Ahmedabad (WHO, PIC/s, EMA, FDA compliant) and Oman. The company has partnered with USV for commercialization of INSUQUICK (biosimilar Insulin Aspart) in India.
Differentiator
Problem solved
Functional benefit
Brands
- INSUQUICK: First biosimilar Insulin Aspart launched in India through partnership with USV for treatment of diabetes
- TrypPRO – AOF
- TrypCELL – AOF
- TrypSOL – AOF
- CarboxyB – AOF
- EKDK – AOF
Products and services
- INSUQUICK (Biosimilar Insulin Aspart) Rapid-acting biosimilar Insulin Aspart developed and manufactured by BioGenomics and commercialized in India through a partnership with USV for the treatment of Type 1 and Type 2 diabetes mellitus.
- BGL-ASP (Insulin Aspart Biosimilar) Rapid-acting insulin analog biosimilar to NovoLog for treatment of Type 1 and Type 2 diabetes mellitus; completed development and entered clinical trials.
- Insulin Aspart Mix (BGL-ASP Mix) Pre-mixed combination of rapid-acting insulin aspart and intermediate-acting insulin, biosimilar to NovoMix, for treatment of Type 1 and Type 2 diabetes mellitus.
- Insulin Glargine Long-acting insulin analog biosimilar to Lantus for treatment of Type 1 and Type 2 diabetes mellitus; under clinical trials.
- Insulin Lispro Rapid-acting insulin analog biosimilar to Humalog for treatment of Type 1 and Type 2 diabetes mellitus; under clinical trials.
- Insulin Degludec Ultra long-acting insulin analog biosimilar to Tresiba for treatment of Type 1 and Type 2 diabetes mellitus.
- Insulin Degludec + Aspart (Ryzodeg biosimilar) Dual insulin combination of ultra long-acting Insulin Degludec with rapid-acting Insulin Aspart, biosimilar to Ryzodeg, for managing blood sugar in Type 1 and Type 2 diabetes mellitus.
- Liraglutide (Victoza biosimilar) GLP-1 receptor agonist biosimilar to Victoza for treatment of Type 2 diabetes mellitus and reduction of cardiovascular risk in Type 2 diabetes patients.
- Liraglutide + Degludec (Xultophy biosimilar) Combination of GLP-1 agonist Liraglutide and long-acting Insulin Degludec, biosimilar to Xultophy, for treatment of Type 2 diabetes mellitus.
- Pembrolizumab (Keytruda biosimilar) Anti-PD-1 monoclonal antibody biosimilar to Keytruda for cancer treatment, targeting the same immune checkpoint pathway.
- Nivolumab (Opdivo biosimilar) Monoclonal antibody biosimilar to Opdivo for treatment of melanoma and other cancers.
- Filgrastim Granulocyte colony-stimulating factor (G-CSF) biosimilar for oncology supportive care, currently in clinical trials; PEGylated forms also in development.
- BGN-25 Topical ointment drug candidate in development for the treatment of diabetic foot ulcers.
- TrypPRO – AOF (Recombinant Trypsin, Proteomics grade) Animal Origin Free recombinant Trypsin expressed in E. coli, GMP grade, with NLT 2500 USP units/mg activity, sold in 1g, 10g, and 100g pack sizes for proteomics applications including recombinant insulin manufacturing, peptide mapping, and protein sequencing.
- TrypCELL – AOF (Recombinant Trypsin, Cell culture grade) Animal Origin Free recombinant Trypsin, GMP grade, with NLT 250 USP units/mg activity, sold in 5g, 10g, 25g, 100g, and 500g pack sizes for cell culture de-adhering and related applications.
- TrypSOL – AOF (Recombinant Trypsin Solution) Ready-to-use Animal Origin Free recombinant Trypsin solution containing approximately 3000 USP units per 500mL bottle, sold in 50mL, 100mL, and 500mL pack sizes for cell culture and other applications.
- CarboxyB – AOF (Recombinant Carboxypeptidase B) Animal Origin Free recombinant Carboxypeptidase B expressed in E. coli, GMP grade, with NLT 100 USP units/mg activity, sold in 1g, 10g, and 100g pack sizes for proteomics applications including insulin manufacturing, peptide mapping, protein sequencing, and acute pancreatitis diagnosis.
- EKDK – AOF (Recombinant Enterokinase) Animal Origin Free recombinant Enterokinase light chain expressed in E. coli, GMP grade, with NLT 5 units/uL activity, sold in 100U, 500U, and 1000U pack sizes for fusion protein cleavage by recognizing the Asp-Asp-Asp-Asp-Lys sequence.
- BioGenomics Residual Trypsin Detection Kit ELISA-based detection kit for quantifying residual Trypsin in biopharmaceutical products, using high-affinity polyclonal antibodies that detect intact and fragmented trypsin with high sensitivity and specificity, independent of enzyme activity.
- BioGenomics Residual CPB Detection Kit ELISA-based detection kit for quantifying residual Carboxypeptidase B in biopharmaceutical products, using high-affinity polyclonal antibodies that detect intact and fragmented CPB regardless of activity status.
- BioGenomics Host Cell Protein (HCP) Detection Kit Sandwich ELISA kit in 96-well plate format for the E. coli expression system, quantifying host cell protein impurities with high sensitivity and broad antibody coverage; allows up to 24 samples per kit with minimal lot-to-lot variation.
Quantifiable outcome
- Recombinant proteins produced in gram levels using AOF technology
- +4 more outcomes
Companies that use BioGenomics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
BioGenomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
BioGenomics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- USVcoreBioGenomics partnered with USV to launch INSUQUICK, the first biosimilar Insulin Aspart for people with diabetes in India. BioGenomics develops and manufactures the biosimilar while USV handles commercialization and distribution in the Indian market. The partnership enables access to affordable insulin for diabetes patients in India.
Scale indicators6 records
Recent moves9 records
Expansion highlights6 records
BioGenomics competitors and assessment
Company assessmentDirect peers
- Biocon Limited: India's largest listed biosimilars company with a portfolio spanning insulin analogs (Insulin Glargine approved in EU/US), mAb biosimilars, and recombinant enzymes. Closest direct competitor to BioGenomics across diabetes, oncology, and B2B enzyme segments.
- Wockhardt Limited: Indian biopharmaceutical company with insulin biosimilars (Wosulin) and recombinant biologics. Directly comparable business model combining biosimilar manufacturing for domestic and emerging-market distribution.
- Dr. Reddy's Laboratories: Major Indian pharmaceutical company with an active biosimilars and biologics pipeline including rituximab and other mAbs. Comparable in targeting regulated-market biosimilar approvals and operating from Indian manufacturing.
- Zydus Lifesciences (Cadila): Indian pharmaceutical group with biosimilar insulin, mAb biosimilars (myBevacizumab approved), and recombinant therapeutics. Already linked to BioGenomics through director Supreet Sharma's prior BD experience at Cadila.
- Aurobindo Pharma: Indian generic and biosimilar manufacturer expanding into complex injectables and biologics. Comparable in targeting biosimilar injectables for regulated markets with vertically integrated manufacturing.
- Glenmark Pharmaceuticals: Indian pharma company with a biosimilars division (Glenmark Specialty) targeting oncology and immunology. Comparable in pursuing biosimilar approvals in regulated markets via Indian manufacturing.
- Lupin Limited: Indian pharmaceutical company with biosimilars and complex generics portfolios including recombinant biologics. Comparable in using India-based biologics manufacturing for both domestic and export markets.
Emerging players
- Alvotech: Iceland-headquartered pure-play biosimilar company focused on mAb biosimilars (adalimumab, ustekinumab, etc.). Comparable in being biosimilar-focused and targeting US/EU approvals, though at a more advanced stage.
- Enzene Biosciences: India-based CDMO and biosimilar developer with a focus on recombinant biologics manufacturing. Comparable as a smaller-scale Indian biosimilar platform player, though with a stronger CDMO orientation than BioGenomics.
Broad incumbents
- Samsung Bioepis: Samsung-backed biosimilar company with approved mAb biosimilars in EU/US (etanercept, adalimumab, trastuzumab, etc.). Comparable in biosimilar mAb focus, but operates at substantially greater scale and with broader commercial partnerships.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BioGenomics social profiles
Digital presenceBioGenomics compliance and trust
Trust signalCompliance9 records
BioGenomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioGenomics leadership team
Management profileNumber of profiles
Profiles13 records
BioGenomics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioGenomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioGenomics
What does BioGenomics do?
BioGenomics develops and manufactures biosimilar biopharmaceuticals focused on anti-diabetes (insulin analogs and GLP-1 receptor agonists) and anti-cancer (monoclonal antibody biosimilars, Filgrastim) therapeutics using an indigenous recombinant protein platform. The company also produces Animal Origin Free (AOF) GMP-grade recombinant enzymes (Trypsin, Carboxypeptidase B, Enterokinase) and ELISA detection kits (residual Trypsin, residual CPB, Host Cell Protein) used by other biopharmaceutical manufacturers.
Is BioGenomics a public or private company?
BioGenomics is a private company. It is classified as state government owned and is currently operating.
When was BioGenomics founded?
BioGenomics was founded in 2002. It employs 101 to 250 people.
Where is BioGenomics based?
BioGenomics is headquartered in Thane, India, in the Asia region.
How does BioGenomics make money?
Three revenue lines are on record. Biopharmaceutical Products are the primary driver. The others are recombinant Proteins and Enzymes and ELISA Detection Kits.
Who are BioGenomics's main competitors?
Direct peers on record are Biocon Limited, Wockhardt Limited, Dr. Reddy's Laboratories, Zydus Lifesciences (Cadila), Aurobindo Pharma, Glenmark Pharmaceuticals and Lupin Limited. Emerging players are Alvotech and Enzene Biosciences. Samsung Bioepis is listed as a broad incumbent.
Does BioGenomics have an API?
No public API is recorded for BioGenomics.
What industry is BioGenomics in?
BioGenomics's product category is Biosimilar Pharmaceuticals. Its primary akta.pro industry code is HLAIAFAB, Insulin & Analog Biosimilars, with a secondary code of HLAAAHAB, Recombinant Protein Biosimilars (hormones, enzymes, cytokines). Its NAICS code is 325414 and its SIC code is 2834.